Cargando…
Drug Repositioning of the α(1)-Adrenergic Receptor Antagonist Naftopidil: A Potential New Anti-Cancer Drug?
Failure of conventional treatments is often observed in cancer management and this requires the development of alternative therapeutic strategies. However, new drug development is known to be a high-failure process because of the possibility of a lower efficacy than expected for the drug or appearan...
Autores principales: | Florent, Romane, Poulain, Laurent, N’Diaye, Monique |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432507/ https://www.ncbi.nlm.nih.gov/pubmed/32727149 http://dx.doi.org/10.3390/ijms21155339 |
Ejemplares similares
-
Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib
por: Florent, Romane, et al.
Publicado: (2020) -
Does prostate volume affect the efficacy of α1D/A: Adrenoceptor antagonist naftopidil?
por: Tanuma, Yasushi, et al.
Publicado: (2016) -
Cutoff level of prostate volume to predict the efficacy of α1-D/A adrenoceptor antagonist, naftopidil
por: Tanuma, Yasushi, et al.
Publicado: (2021) -
Beta adrenergic antagonists and antianginal drugs
por: Stever, Lindsey M., et al.
Publicado: (2021) -
Crystal structures, absolute configurations and molecular docking studies of naftopidil enantiomers as α(1D)-adrenoceptor antagonists
por: Xu, Wei, et al.
Publicado: (2017)